SCHEMBL5144939

SCHEMBL5144939

COc1ccc(C(C)=O)c(OC)c1C

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.51
MAPT P10636 4/20 0.49
LMNA P02545 4/20 0.49
ALDH1A1 P00352 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GAA P10253 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
MAPK1 P28482 2/20 0.45
CYP3A4 P08684 2/20 0.42
HPGD P15428 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
KCNA3 P22001 1/20 0.40
PDE4A P27815 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779654 0.88 LMNA (0.51) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL10740410 0.85 LMNA (0.56) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL4309406 0.85 MAPT (0.62) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL1421887 0.84 ALDH1A1 (0.59) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL30069060 0.84 ALDH1A1 (0.59) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL16513023 0.83 HTT (0.50) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL6667907 0.82 ALDH1A1 (0.43) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL5512898 0.81 MAPT (0.58) HTTMAPTLMNAALDH1A1TDP1
SCHEMBL23302233 0.80 HTT (0.58) HTTMAPTLMNATDP1MEN1
SCHEMBL17041239 0.79 ALDH1A1 (0.41) HTTMAPTLMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0674233-B1 Recording sheets XEROX CORP (US) 2000-05-24 EP claimed
US-5928765-A Recording sheets XEROX CORPORATION (US) 1999-07-27 US claimed
EP-0674233-A2 Recording sheets XEROX CORPORATION (US) 1995-09-27 EP claimed
WO-2021085321-A1 RESIN COMPOSITION, RESIN SHEET, CURED FILM, METHOD FOR MANUFACTURING CURED FILM, SEMICONDUCTOR DEVICE, ORGANIC EL DISPLAY DEVICE, AND DISPLAY DEVICE 東レ株式会社 2021-05-06 WO disclosed
US-20160096795-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES UNIGEN INC (US) 2016-04-07 US disclosed
US-9045405-B2 Compounds and methods for preparation of diarylpropanes UNIGEN, INC. (US) 2015-06-02 US disclosed
US-20140235899-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES UNIGEN, INC. (US) 2014-08-21 US disclosed
WO-2012129260-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES UNIGEN, INC. (US) 2012-09-27 WO disclosed
US-20120245393-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES UNIGEN, INC. (US) 2012-09-27 US disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070203080-A1 New Drug Delivery System for Crossing the Blood Brain Barrier THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-30 US disclosed
WO-2007095630-A2 NEW UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed
WO-2007095630-A2 NEW UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed
WO-2007095631-A2 NEW DRUG DELIVERY SYSTEM FOR CROSSING THE BLOOD BRAIN BARRIER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed
WO-2007095631-A2 NEW DRUG DELIVERY SYSTEM FOR CROSSING THE BLOOD BRAIN BARRIER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed
EP-0674233-B1 Recording sheets XEROX CORP (US) 2000-05-24 EP disclosed
US-5928765-A Recording sheets XEROX CORPORATION (US) 1999-07-27 US disclosed
EP-0674233-A2 Recording sheets XEROX CORPORATION (US) 1995-09-27 EP disclosed
US-5451458-A Electrography XEROX CORPORATION (US) 1995-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096795-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES DDT, QDPR, NPY1R HTT 1099/4885MAPT 208/4885LMNA 514/4885
US-20120245393-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES DDT, QDPR, NPY1R HTT 1099/4885MAPT 208/4885LMNA 514/4885
US-20140235899-A1 COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES DDT, QDPR, NPY1R HTT 1099/4885MAPT 208/4885LMNA 514/4885
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE NDUFB7, NDUFB1, NDUFB3 HTT 1214/4885MAPT 4254/4885LMNA 1593/4885
US-20070203080-A1 New Drug Delivery System for Crossing the Blood Brain Barrier NDUFB5, NDUFB7, NDUFB3 HTT 1242/4885MAPT 1404/4885LMNA 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.